Skip Nav Destination
A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in β-thalassemia major (CORDELIA)
A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma
Childhood high-risk acute lymphoblastic leukemia in first remission: results after chemotherapy or transplant from the AIEOP ALL 2000 study
Leukocyte cell-derived chemotaxin 2 (LECT2)–associated amyloidosis is a frequent cause of hepatic amyloidosis in the United States
Safe mobilization of CD34+ cells in adults with β-thalassemia and validation of effective globin gene transfer for clinical investigation
B-cell receptors expressed by lymphomas of hepatitis C virus (HCV)–infected patients rarely react with the viral proteins
JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes
Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia
Issue Archive
Table of Contents
INSIDE BLOOD
BLOOD WORK
PLENARY PAPER
A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in β-thalassemia major (CORDELIA)
Clinical Trials & Observations
Dudley J. Pennell,on behalf of the CORDELIA study investigators,John B. Porter,on behalf of the CORDELIA study investigators,Antonio Piga,on behalf of the CORDELIA study investigators,Yongrong Lai,on behalf of the CORDELIA study investigators,Amal El-Beshlawy,on behalf of the CORDELIA study investigators,Khawla M. Belhoul,on behalf of the CORDELIA study investigators,Mohsen Elalfy,on behalf of the CORDELIA study investigators,Akif Yesilipek,on behalf of the CORDELIA study investigators,Yurdanur Kilinç,on behalf of the CORDELIA study investigators,Tomasz Lawniczek,on behalf of the CORDELIA study investigators,Dany Habr,on behalf of the CORDELIA study investigators,Marianne Weisskopf,on behalf of the CORDELIA study investigators,Yiyun Zhang,on behalf of the CORDELIA study investigators,Yesim Aydinok,on behalf of the CORDELIA study investigators
BLOOD SPOTLIGHT
CLINICAL TRIALS AND OBSERVATIONS
A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma
Clinical Trials & Observations
Paul G. Richardson,Wanling Xie,Sundar Jagannath,Andrzej Jakubowiak,Sagar Lonial,Noopur S. Raje,Melissa Alsina,Irene M. Ghobrial,Robert L. Schlossman,Nikhil C. Munshi,Amitabha Mazumder,David H. Vesole,Jonathan L. Kaufman,Kathleen Colson,Mary McKenney,Laura E. Lunde,John Feather,Michelle E. Maglio,Diane Warren,Dixil Francis,Teru Hideshima,Robert Knight,Dixie-Lee Esseltine,Constantine S. Mitsiades,Edie Weller,Kenneth C. Anderson
Childhood high-risk acute lymphoblastic leukemia in first remission: results after chemotherapy or transplant from the AIEOP ALL 2000 study
Clinical Trials & Observations
Valentino Conter,Maria Grazia Valsecchi,Rosanna Parasole,Maria Caterina Putti,Franco Locatelli,Elena Barisone,Luca Lo Nigro,Nicola Santoro,Maurizio Aricò,Ottavio Ziino,Andrea Pession,Anna Maria Testi,Concetta Micalizzi,Fiorina Casale,Marco Zecca,Gabriella Casazza,Paolo Tamaro,Gaetano La Barba,Lucia Dora Notarangelo,Daniela Silvestri,Antonella Colombini,Carmelo Rizzari,Andrea Biondi,Giuseppe Masera,Giuseppe Basso
Leukocyte cell-derived chemotaxin 2 (LECT2)–associated amyloidosis is a frequent cause of hepatic amyloidosis in the United States
Clinical Trials & Observations
Brief Report
Oana M. Mereuta,Jason D. Theis,Julie A. Vrana,Mark E. Law,Karen L. Grogg,Surendra Dasari,Vishal S. Chandan,Tsung-Teh Wu,Victor H. Jimenez-Zepeda,Rafael Fonseca,Angela Dispenzieri,Paul J. Kurtin,Ahmet Dogan
GENE THERAPY
Safe mobilization of CD34+ cells in adults with β-thalassemia and validation of effective globin gene transfer for clinical investigation
Brief Report
Farid Boulad,Xiuyan Wang,Jinrong Qu,Clare Taylor,Leda Ferro,Garyfalia Karponi,Shirley Bartido,Patricia Giardina,Glenn Heller,Susan E. Prockop,Aurelio Maggio,Michel Sadelain,Isabelle Rivière
LYMPHOID NEOPLASIA
Mutations in linker histone genes HIST1H1 B, C, D, and E; OCT2 (POU2F2); IRF8; and ARID1A underlying the pathogenesis of follicular lymphoma
Hongxiu Li,Mark S. Kaminski,Yifeng Li,Mehmet Yildiz,Peter Ouillette,Siân Jones,Heather Fox,Kathryn Jacobi,Kamlai Saiya-Cork,Dale Bixby,Daniel Lebovic,Diane Roulston,Kerby Shedden,Michael Sabel,Lawrence Marentette,Vincent Cimmino,Alfred E. Chang,Sami N. Malek
B-cell receptors expressed by lymphomas of hepatitis C virus (HCV)–infected patients rarely react with the viral proteins
Brief Report
Patrick P. Ng,Chiung-Chi Kuo,Stanley Wang,Shirit Einav,Luca Arcaini,Marco Paulli,Carol S. Portlock,Joseph Marcotrigiano,Alexander Tarr,Jonathan Ball,Ronald Levy,Shoshana Levy
MYELOID NEOPLASIA
JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes
Clinical Trials & Observations
Elisa Rumi,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators,Daniela Pietra,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators,Virginia Ferretti,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators,Thorsten Klampfl,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators,Ashot S. Harutyunyan,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators,Jelena D. Milosevic,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators,Nicole C. C. Them,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators,Tiina Berg,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators,Chiara Elena,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators,Ilaria C. Casetti,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators,Chiara Milanesi,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators,Emanuela Sant’Antonio,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators,Marta Bellini,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators,Elena Fugazza,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators,Maria C. Renna,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators,Emanuela Boveri,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators,Cesare Astori,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators,Cristiana Pascutto,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators,Robert Kralovics,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators,Mario Cazzola,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators
Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia
Clinical Trials & Observations
Brief Report
Giada Rotunno,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators,Carmela Mannarelli,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators,Paola Guglielmelli,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators,Annalisa Pacilli,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators,Alessandro Pancrazzi,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators,Lisa Pieri,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators,Tiziana Fanelli,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators,Alberto Bosi,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators,Alessandro M. Vannucchi,on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators
PLATELETS AND THROMBOPOIESIS
Functional platelet defects in children with severe chronic ITP as tested with 2 novel assays applicable for low platelet counts
Esther R. van Bladel,Annemieke G. Laarhoven,Laila B. van der Heijden,Katja M. Heitink-Pollé,Leendert Porcelijn,C. Ellen van der Schoot,Masja de Haas,Mark Roest,Gestur Vidarsson,Philip G. de Groot,Marrie C. A. Bruin
RED CELLS, IRON, AND ERYTHROPOIESIS
Unbiased RNAi screen for hepcidin regulators links hepcidin suppression to proliferative Ras/RAF and nutrient-dependent mTOR signaling
Katarzyna Mleczko-Sanecka,Franziska Roche,Ana Rita da Silva,Debora Call,Flavia D’Alessio,Anan Ragab,Philip E. Lapinski,Ramesh Ummanni,Ulrike Korf,Christopher Oakes,Georg Damm,Lorenza A. D’Alessandro,Ursula Klingmüller,Philip D. King,Michael Boutros,Matthias W. Hentze,Martina U. Muckenthaler
Mutations in Krüppel-like factor 1 cause transfusion-dependent hemolytic anemia and persistence of embryonic globin gene expression
Vip Viprakasit,Supachai Ekwattanakit,Suchada Riolueang,Nipon Chalaow,Chris Fisher,Karen Lower,Hitoshi Kanno,Kalaya Tachavanich,Sasithorn Bejrachandra,Jariya Saipin,Monthana Juntharaniyom,Kleebsabai Sanpakit,Voravarn S. Tanphaichitr,Duantida Songdej,Christian Babbs,Richard J. Gibbons,Sjaak Philipsen,Douglas R. Higgs
THROMBOSIS AND HEMOSTASIS
TRANSPLANTATION
Transplantation for children with acute myeloid leukemia: a comparison of outcomes with reduced intensity and myeloablative regimens
Menachem Bitan,Wensheng He,Mei-Jie Zhang,Hisham Abdel-Azim,Mouhab Fakhreddine Ayas,Bella Bielorai,Paul A. Carpenter,Mitchell S. Cairo,Miguel Angel Diaz,John T. Horan,Sonata Jodele,Carrie L. Kitko,Kirk R. Schultz,Morris Kletzel,Kimberly A. Kasow,Leslie E. Lehmann,Parinda A. Mehta,Nirali Shah,Michael A. Pulsipher,Tim Prestidge,Adriana Seber,Shalini Shenoy,Ann E. Woolfrey,Lolie C. Yu,Stella M. Davies
ERRATA
-
Cover Image
Cover Image
![issue cover]()
Colorized scanning electron micrograph of closely packed polyhedrocytes (red), or polyhedral erythrocytes, formed by compression of erythrocytes by platelets (blue) and fibrin (yellow) during clot contraction (or retraction). Polyhedrocytes form a nearly impermeable seal to stem bleeding and help prevent vascular obstruction, but confer resistance to fibrinolysis. See the article by Cines et al on page 1596.
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkBack Matter
- PDF Icon PDF LinkAdvertising
- PDF Icon PDF LinkEditorial Board
Advertisement intended for health care professionals
Email alerts
Advertisement intended for health care professionals
